13F Holdings
中文EN

DMRA Damora Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1800315 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,741.0%
TTM EPS YoY179.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-116.1%
ROA-107.4%
ROIC (approx.)-331.3%
Asset turnover—

Leverage & solvency

Liabilities / assets6.9%
Debt / equity0.00x
Current ratio14.80x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.20x
Accruals ratio-85.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$26.88M$6.40M$23.77M$48.21M$38.49M
SG&A expense$9.69M$10.50M$12.69M$13.00M$13.74M
Operating income-$210.87M-$22.26M-$39.91M-$61.21M-$52.23M
Pretax income-$209.79M-$21.40M-$38.35M-$61.62M-$51.75M
Income tax$50,000$41,000$0$0$0
Net income-$209.84M-$21.44M-$38.35M-$61.62M-$51.75M
EBITDA-$210.85M-$22.24M-$39.64M-$61.16M-$52.21M
EPS (basic)3.98-18.53-36.08-2.43-2.05
EPS (diluted)3.98-18.53-36.08-2.43-2.05
Dividends declared per share0.000.00——0.00
Weighted avg. shares (diluted)1.36M1.16M1.06M25.41M25.26M
Banking
Net interest income$1.17M$844,000$1.69M$722,000$156,000
Balance sheet
Cash & equivalents$257.62M$14.18M$21.46M$32.79M$62.56M
Short-term investments$0—$11.69M$27.44M$37.63M
Current assets$260.42M$16.84M$36.77M$63.91M$110.10M
PP&E, net$36,000$57,000$78,000$357,000$203,000
Total assets$260.53M$17.13M$38.23M$73.19M$122.22M
Current liabilities$20.07M$1.20M$5.83M$11.11M$4.54M
Total liabilities$20.15M$1.30M$5.90M$11.44M$4.99M
Shareholders' equity$239.04M$14.47M$32.33M$61.75M$117.22M
Shares outstanding1.60M1.32M1.08M25.65M25.26M
Cash flow statement
Operating cash flow-$6.73M-$18.62M-$36.91M-$42.93M-$52.31M
Capital expenditure———$196,000$223,000
Free cash flow———-$43.13M-$52.53M
Investing cash flow-$17.37M$11.65M$22.33M$12.38M-$48.05M
Financing cash flow$266.84M—$2.88M$507,000—
Depreciation & amortization$22,000$21,000$269,000$42,000$20,000
Stock-based compensation$998,000$3.24M$5.43M$5.57M$4.48M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.